Single-agent salvage chemotherapy Response rates with single-agent chemotherapy in gemcitabine-pretreated patients are low (≤ 6%). Based on Phase II trials, efficacy data for single-agent ...

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

Perioperative durvalumab improved upon neoadjuvant chemotherapy in patients with cisplatin-eligible MIBC in the NIAGARA trial.

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...

Future directions for ctDNA in the preoperative setting involve assaying circulating or urinary cell-free DNA through NGS after UTUC diagnosis. This approach aims to improve accurate staging and ...

To the best of our knowledge, this is the first study to provide information about feasibility and tolerability of the combination cisplatin/gemcitabine ... courses of chemotherapy, with a high ...

Phase I/Ib study of afatinib with capecitabine in patients with refractory solid tumors and pancreaticobiliary cancers. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

The data revealed that the use of the Trans-Arterial Micro-Perfusion (TAMP) device resulted in greater drug potency and fewer ...

They were used on five patients, and four of them are now either in remission or cancer-free. Read more at straitstimes.com.